Baylor College of Medicine

Giving life to possible

Bibliography

Poster and Platform Presentations — George J. Hutton, M.D.

Click on the Expand plus sign sign to list the poster and platform presentations by year. Then click on the link to view that presentation.

2024

Collapse All | Expand All

 

    American Academy of Neurology (AAN)
    76th Annual Meeting in Denver, Colo. (April 13-18, 2024)
    • Patel H, Hutton G. A case of immune checkpoint inhibitor (ICI) use in multiple sclerosis. Presented at the American Academy of Neurology (AAN), 76th Annual Meeting in Denver, Colo. (April 13-18, 2024).  

2023

Collapse All | Expand All

 

    9th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
    Milan, Italy (Oct. 11-13, 2023)
    • Rempe T, Elfasi A, Alkabie S, Alison C, Rodriguez E, Castrodad-Molina R, et al. Increased intracranial pressure - A rare complication of optic neuritis in myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Mult Scler. 2023;29(3S):681. 
    • Rempe T, Elfasi A, Alkabie S, Rodriguez E, Castrodad-Molina R, Montalvo M, et al. Predictors for a relapsing course of myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Mult Scler. 2023;29(3S):119-20. [Platform Presentation] 
    Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
    Annual Forum in San Diego, Calif. (Feb. 23-25, 2023)
    • Elfasi A, Alkabie S, Rodriguez E, Timmons G, Montalvo Perero M, Castrodad Molina R, et al. Anti-myelin oligodendrocyte glycoprotein (anti-MOG) meningoencephalitis. Mult Scler. 2023;29(2S):160-1. 
    • Elfasi A, Alkabie S, Rodriguez E, Timmons G, Montalvo Perero M, Castrodad Molina R, et al. Treatment response to different immunotherapies in relapsing myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Mult Scler. 2023;29(2S):175. 

2022

Collapse All | Expand All

 

    Professional Society for Health Economics and Outcomes Research (ISPOR)
    2022 Annual Meeting in Washington, DC (May 16-18, 2022)
    • Earla JR, Hutton GJ, Aparasu RR. Comparative adherence trajectories across oral disease-modifying agents in multiple sclerosis. Value Health. 2022;25(7 suppl):S303. 
    • Earla JR, Hutton GJ, Aparasu RR. Factors associated with prescribing of teriflunomide and dimethyl fumarate versus fingolimod in multiple sclerosis. Value Health. 2022;25(7 suppl):S482. 

<2021

Collapse All | Expand All

 

    Professional Society for Health Economics and Outcomes Research (ISPOR)
    Virtual 2021 Annual Meeting (May 17-20, 2021)
    • Earla J, Hutton GJ, Thornton JD, Chen H, Johnson ML, Aparasu RR. Effect of different variance estimation methods with inverse probability treatment weights (IPTW) on comparative effectiveness measure in multiple sclerosis. Value Health. 2021;24(Suppl 1):S2. 
    • Talwar A, Earla J, Hutton GJ, Aparasu RR. Factors associated with prescribing of disease-modifying agents among older adults with multiple sclerosis: A real-world analysis of electronic medical records. Value Health. 2021;24(Suppl 1):S171-2. 
    International Society for Pharmacoepidemilogy (ISPE)
    International Conference on Pharmacoepidemilogy (ICPE) All Access 2020 virtual event (Sept. 16-17, 2020)
    • Earla JR, Hutton GJ, Thornton JD, Chen H, Johnson ML, Aparasu RR. Comparative treatment effectiveness of oral fingolimod and injectable disease modifying agents in multiple sclerosis. Pharmacoepidemiol Drug Saf. 2020;29(Suppl 3):118. 
    Professional Society for Health Economics and Outcomes Research (ISPOR)
    Virtual 2020 Annual Meeting (May 18-20, 2020)
    • Earla JR, Hutton GJ, Thornton JD, Chen H, Johnson ML, Aparasu R. Comparative adherence trajectories of oral fingolimod and injectable disease modifying agents in multiple sclerosis. Value Health. 2020;23(Suppl 1):S279. 
    • Earla JR, Hutton GJ, Thornton JD, Chen H, Johnson ML, Aparasu R. Factors associated with prescribing of oral fingolimod in multiple sclerosis. Value Health. 2020;23(Suppl 1):S272. 
    American Academy of Neurology (AAN)
    72nd Annual Meeting in Toronto, Ontario, Canada (April 25 - May 1, 2020)
    • Celius EG, Oh J, Achiron A, Compston DAS, Devonshire V, Hellwig K, et al. Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years. Neurology. 2020;94(15 Suppl):169. 
    Professional Society for Health Economics and Outcomes Research (ISPOR)
    2019 Annual Meeting in New Orleans, La. (May 18-22, 2019)
    • Earla JR, Hutton GJ, Thornton JD, Aparasu RR. Factors associated with prescribing of oral disease modifying agents in multiple sclerosis. Value Health. 2019;22(Suppl 2):S390. 
    • Earla JR, Thornton JD, Hutton GJ, Aparasu RR. Healthcare expenditure burden in multiple sclerosis: Marginal costs based on national level data. Value Health. 2019;22(Suppl 2):S277. 
    American Academy of Neurology (AAN)
    71st Annual Meeting in Philadelphia, Penn. (May 4-10, 2019)
    • Balasa A, Hutton GJ. Leprosy in two patients with relapsing remitting multiple sclerosis (RRMS) treated with fingolimod. Neurology. 2019;92(15 Suppl):P4.2-012.  [View poster]
    • Cuascut Lassus FX, Dunham SR, Hutton GJ. Fingolimod related cryptococcal meningitis and immune reconstitution inflammatory syndrome in two patients with multiple sclerosis. Neurology. 2019;92(15 Suppl):P4.2-011.  [View poster]
    American Academy of Neurology (AAN)
    70th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)
    • Orozco Leon V, Dunham SR, Hutton G. Long-term outcomes of patients treated for idiopathic relapsing transverse myelitis. Neurology. 2018;90(15 Suppl):P6.418.  [View poster]
    Consortium of Multiple Sclerosis Centers (CMSC)
    31st Annual Meeting in New Orleans, La. (May 24-27, 2017)
    • Orozco-Leon VI, Dunham SR, Hutton GJ. Patient-reported overactive bladder in neuromyelitis optica spectrum disorder. Presented at the Consortium of Multiple Sclerosis Centers (CMSC), 31st Annual Meeting in New Orleans, La. (May 24-27, 2017).   [View poster]
    • Orozco-Leon VI, Dunham SR, Hutton GJ. Prevalence of self-reported sexual dysfunction in neuromyelitis optica spectrum disorder. Presented at the Consortium of Multiple Sclerosis Centers (CMSC), 31st Annual Meeting in New Orleans, La. (May 24-27, 2017).   [View poster]
    Consortium of Multiple Sclerosis Centers (CMSC)
    30th Annual Meeting in National Harbor, Md. (June 1-4, 2016)
    • Mahmoud R, Hutton GJ, Altman KW, Carter F, Dunham SR. Prevalence of dysphagia in multiple sclerosis and correlation with disability. Presented at the Consortium of Multiple Sclerosis Centers (CMSC), 30th Annual Meeting in National Harbor, Md. (June 1-4, 2016). [Platform Presentation] 
    • Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Georges GE, et al. Five-year outcomes of HALT-MS: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe relapsing-remitting multiple sclerosis. Presented at the Consortium of Multiple Sclerosis Centers (CMSC), 30th Annual Meeting in National Harbor, Md. (June 1-4, 2016). [Platform Presentation] 
    Consortium of Multiple Sclerosis Centers (CMSC)
    27th Annual Meeting in Orlando, Fla. (May 29 - June 1, 2013)
    • Dragan E, Hutton G. Neuromyelitis optica presenting as multiple sclerosis worsening on natalizumab. Int J MS Care. 2013;15 Suppl 3:89-90.  [View poster]
    • Dragan E, Hutton G. Treatment of idiopathic relapsing transverse myelitis. Int J MS Care. 2013;15 Suppl 3:54.  [View poster]
    • Dragan E, Hutton G, Birnbaum Y. Case series of cardiac complications during fingolimod first dose observation period. Int J MS Care. 2013;15 Suppl 3:89.  [View poster]
    • Dragan E, Saldana-King T, Hutton G. Efficacy of fingolimod in ethnic minorities. Int J MS Care. 2013;15 Suppl 3:90.  [View poster]
    • Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Georges GE, et al. Two-year follow-up results of the HALT MS clinical trial (ITN033AI). Int J MS Care. 2013;15 Suppl 3:21. 
    American Academy of Neurology (AAN)
    65th Annual Meeting in San Diego, Calif. (March 16-23, 2013)
    • Dragan E, Hutton G. Treatment of idiopathic relapsing transverse myelitis. Neurology. 2013;80(Meeting Abstracts 1):P02.124.  [View poster]
    • Thrower B, Yapundich R, Applebee A, Hutton G, Klingler M, Henney H, et al. Safety and efficacy of 5 mg and 10 mg dalfampridine extended release tablets in patients with multiple sclerosis: First results from a double-blind, placebo-controlled trial. Neurology. 2013;80(Meeting Abstracts 1):P04.096.  [View poster]
    Baylor College of Medicine (BCM)
    Current Neurology 2012 in Houston, Texas (Nov. 3-4, 2012)
    • Stosic M, De Jesus P, McCarthy J, Hutton GJ, Rivera VM. Multiple sclerosis patient treated with natalizumab develops immune thrombocytopenic purpura. Presented at the Baylor College of Medicine (BCM), Current Neurology 2012 in Houston, Texas (Nov. 3-4, 2012).   [View poster]
    American Academy of Neurology (AAN)
    63rd Annual Meeting in Honolulu, Hawaii (April 9-16, 2011)
    • Avila M, Prieto P, Avila-Ornelas J, Stosic M, Amin A, Hutton GJ, et al. Distal limb discoloration in patients with multiple sclerosis - Case series of 41 patients. Neurology. 2011;76(Suppl 4):A290.  [View poster]
    • Qiu C, Avila M, Hutton G. Incidence of multiple sclerosis in patients presenting with neurogenic bladder. Neurology. 2011;76(Suppl 4):A600.  [View poster]
    Consortium of Multiple Sclerosis Centers (CMSC)
    24th Annual Meeting in San Antonio, Texas (June 2-5, 2010)
    • Avila J, Avila M, Stosic M, Robles L, Prieto PG, Hutton GJ, et al. The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. Int J MS Care. 2010;12 Suppl 1:13.  [View poster]
    • Avila M, Hutton G, Rivera VM. Recurrent and multiphasic disseminated encephalomyelitis, case series. Int J MS Care. 2010;12 Suppl 1:14.  [View poster]
    • Avila M, Prieto P, Robles L, Avila J, Stosic M, Hutton G, et al. Distal lower limb discoloration in patients with multiple sclerosis. Int J MS Care. 2010;12 Suppl 1:13-4.  [View poster]
    • Avila M, Prieto P, Robles L, Stosic M, Avila J, Hutton G, et al. Sleep disorders in multiple sclerosis. Int J MS Care. 2010;12 Suppl 1:13.  [View poster]
    • Robles L, Hutton GJ, Rivera VM. Use of natalizumab in Hispanic patients with relapsing remitting multiple sclerosis. Int J MS Care. 2010;12 Suppl 1:58.  [View poster]
    • Thorne BJ, Perez FI, Rivera VM, Hutton GJ. Computer-assisted cognitive rehabilitation for multiple sclerosis — Updated findings. Int J MS Care. 2010;12 Suppl 1:69.  [View poster]
    American Academy of Neurology (AAN)
    62nd Annual Meeting in Toronto, Canada (April 10-17, 2010)
    • Hutton G, Avila M, Prieto PG, Avila J, Rivera V. Multiple sclerosis and other CNS demyelination after treatment with tumor necrosis factor alpha blockers. Neurology. 2010;74(9 Suppl 2):A371.  [View poster]
    Society for Neuroscience (SFN)
    39th Annual Meeting in Chicago, Ill. (Oct. 17-21, 2009)
    • Helekar SA, Shin JC, Mattson BJ, Bartley K, Stosic M, Saldana-King T, et al. Functional correlation of brain loci during cognitive tasks in multiple sclerosis. Program No. 244.25. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009. Online.  [View poster]
    American Neurological Association (ANA)
    134th Annual Meeting in Baltimore, Md. (Oct. 11-14, 2009)
    • Bernitsas E, Hutton GJ, Rivera VM. Deep brain stimulation in multiple sclerosis-related Holmes' tremor. Ann Neurol. 2009;66 Suppl 1:S40.  [View poster]
    Consortium of Multiple Sclerosis Centers (CMSC)
    23rd Annual Meeting in Atlanta, Ga. (May 27-30, 2009)
    • Avila M, Prieto PG, Robles L, Hutton GJ, Rivera VM. Clinical and radiographic improvement of an acutely aggressive case of multiple sclerosis treated with cyclophosphamide. Int J MS Care. 2009;11 Suppl 2:52-3.  [View poster]
    • Avila M, Robles L, Prieto P, Bernitsas E, Stosic M, Hutton GJ, et al. Prevalence of sleep disorders in multiple sclerosis. Int J MS Care. 2009;11 Suppl 2:83.  [View poster]
    • Bernitsas E, Hutton GJ, Rivera VM. Spasmodic dysphonia in MS: A rare symptom or a possible association? Int J MS Care. 2009;11 Suppl 2:31-2.  [View poster]
    • Bernitsas E, Stosic M, Hutton GH, Rivera VM. Seizures in MS patients: A retrospective study. Int J MS Care. 2009;11 Suppl 2:32.  [View poster]
    • Hutton GJ, Bowen J, Forman S, Frohman E, Griffith L, Kraft G, et al. HALT-MS--Intense immunosuppression and stem cell transplantation for RRMS. Int J MS Care. 2009;11 Suppl 2:4.  [View platform presentation]
    • Robles L, Prieto P, DeAlvare L, Hutton GJ, Rivera VM. Diffuse white matter abnormalities and neurologic manifestations in a patient with anti-ro positive antibodies. Case Report. Int J MS Care. 2009;11 Suppl 2:43.  [View poster]
    • Robles L, Prieto P, Rivera VM, Hutton GJ. Occurrence of herpes zoster in multiple sclerosis patients treated with natalizumab. Int J MS Care. 2009;11 Suppl 2:43.  [View poster]
    American Academy of Neurology (AAN)
    61st Annual Meeting in Seattle, Wash. (April 25 - May 2, 2009)
    • Wundes A, Bowen J, Kraft G, Hutton G, Openshaw H, Forman S, et al. HALT MS — Phase II clinical trial of high dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation for active relapsing- remitting multiple sclerosis. Neurology. 2009;72(11 Suppl 3):A356.  [View poster]
    National Multiple Sclerosis Society (NMSS)
    Tykeson Fellows Conference in Chicago, Ill. (Nov. 4-7, 2008)
    • Bernitsas E, Hutton GJ, Rivera VM. Marburg's disease and neuromyelitis optica in brother/sister. Presented at the National Multiple Sclerosis Society (NMSS), Tykeson Fellows Conference in Chicago, Ill. (Nov. 4-7, 2008).   [View poster]
    World Congress on Treatment and Research in Multiple Sclerosis (ACTRIMS + ECTRIMS + LACTRIMS)
    Montreal, Quebec, Canada (Sept. 17-20, 2008)
    • Avila M, Suarez GA, Brandt D, Ramirez J, Hutton GJ, Rivera VM. Menstrual cycle and menopause in patients with multiple sclerosis. How do these affect the symptoms of disease? Mult Scler. 2008;14 Suppl 1:S155.  [View poster]
    • Chaliman RT, Perez FI, Suarez GA, Rivera VM, Hutton GJ. Longitudinal individualized analysis of computer-based cognitive rehabilitation in multiple sclerosis. Mult Scler. 2008;14 Suppl 1:S152.  [View poster]
    • Suarez GA, Avila M, Brandt D, Rivera VM, Hutton GJ. Magnetic resonance imaging findings in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2008;14 Suppl 1:S223.  [View poster]
    Consortium of Multiple Sclerosis Centers (CMSC)
    22nd Annual Meeting in Denver, Colo. (May 28-31, 2008)
    • Suarez-Zambrano GA, Ramirez J, Avila M, Brandt D, Escobar BH, Hutton GJ, et al. Silent MRI white matter lesions in patients with CIS suggestive of multiple sclerosis. Int J MS Care. 2008;10 Suppl 1:52.  [View poster]
    American Academy of Neurology (AAN)
    60th Annual Meeting in Chicago, Ill. (April 12-19, 2008)
    • Cohen J, Imrey P, Calabresi P, Chakraborty S, Edwards K, Eickenhorst T, et al. Site performance in an investigator-run multiple sclerosis clinical trial. Neurology. 2008;70(11 Suppl 1):A84.  [View poster]
    • Kraft GH, Bowen JD, Openshaw H, Forman SJ, Frohman EM, Griffith LM, et al. Phase II clinical trial (HALT-MS: Immune tolerance network) of high dose immunosuppressive therapy (HDIT) and autologous hematopoetic stem cell transplantation (AHSCT) for active relapsing-remitting (RR) multiple sclerosis (MS): Early results. Neurology. 2008;70(11 Suppl 1):A95.  [View poster]
    • Suarez-Zambrano GA, Pena JA, Avila M, Hutton GJ, Rivera VM. Frequency and severity of restless legs syndrome in multiple sclerosis: A population study from southeast Texas. Neurology. 2008;70(11 Suppl 1):A334.  [View poster]
    Mexican Academy of Neurology
    31st Annual Meeting in Monterrey, Mexico (Oct. 31 - Nov. 5, 2007)
    • Avila M, Ramirez J, Suarez-Zambrano GA, Hutton GJ, Rivera VM. Multiple sclerosis and antiphospholipid syndrome: Case report. Presented at the Mexican Academy of Neurology, 31st Annual Meeting in Monterrey, Mexico (Oct. 31 - Nov. 5, 2007).   [View poster]
    • Avila M, Suarez-Zambrano GA, Ramirez J, Hutton GJ, Rivera VM. Encefalomielitis diseminada recurrente y multifásica reporte de 2 casos. Presented at the Mexican Academy of Neurology, 31st Annual Meeting in Monterrey, Mexico (Oct. 31 - Nov. 5, 2007). [Recurrent Disseminated Encephalomyelitis: Report of 2 Cases]  [View poster]
    • Suarez-Zambrano GA, Escobar BH, Avila M, Ramirez J, Hutton GJ, Rivera VM. Experience with natalizumab in a group of ms patients from southeast Texas. Presented at the Mexican Academy of Neurology, 31st Annual Meeting in Monterrey, Mexico (Oct. 31 - Nov. 5, 2007).   [View poster]
    European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
    23rd Congress in Prague, Czech Republic (Oct. 11-14, 2007)
    • Hutton GJ, Avila M, Suarez-Zambrano GA, Ramirez J, Rivera VM. Recurrent disseminated encephalomyelitis: Report of 2 cases. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 23rd Congress in Prague, Czech Republic (Oct. 11-14, 2007).   [View poster]
    • Hutton GJ, Suarez-Zambrano GA, Jafree I, Landero S, Avila M, Rivera VM. Is restless legs syndrome more frequent and severe in the multiple sclerosis population? Study in multiple sclerosis patients from southeast Texas. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 23rd Congress in Prague, Czech Republic (Oct. 11-14, 2007).   [View poster]
    Colombian Academy of Neurology
    VIII Meeting in Cali, Colombia (Aug. 16-19, 2007)
    • Suarez-Zambrano GA, Avila M, Landero S, Jafree I, Escobar BH, Ramirez J, et al. Experiencia con natalizumab en 40 pacientes con esclerosis multiple exacerbacion remision. Presented at the Colombian Academy of Neurology, VIII Meeting in Cali, Colombia (Aug. 16-19, 2007).   [View poster]
    Consortium of Multiple Sclerosis Centers (CMSC)
    21st Annual Meeting in Washington, DC (May 30 - June 2, 2007)
    • Jafree I, Hashmi K, Landero S, Suarez G, Hutton GJ, Rivera VM. Multiple sclerosis and other autoimmune diseases. Int J MS Care. 2007;9(2):65.  [View poster]
    • Landero S, Rivera VM, Hutton GJ, Suarez-Zambrano GA, Ramirez J. Behavior of multiple sclerosis during pregnancy and after delivery. Int J MS Care. 2007;9(2):67.  [View poster]
    • Nash R, Openshaw H, Bowen JD, Forman SJ, Stuve O, Hutton GJ, et al. A phase II study of high-dose immunosuppressive therapy (HDIT) using carmustine, etoposide, cytarabine, and melphalan (beam) + thymoglobulin, and autologous CD34+ hematopoietic stem cell transplant (HCT) for the treatment of poor prognosis multiple sclerosis. HALT-MS. Int J MS Care. 2007;9(2):90.  [View poster]
    • Suarez-Zambrano GA, Landero S, Jafree I, Hutton GJ, Rivera VM. Frequency and severity of restless legs syndrome in ms patients from southeast Texas. Int J MS Care. 2007;9(2):77.  [View poster]
    • Suarez-Zambrano GA, Landero S, Jafree I, Hutton GJ, Rivera VM. Multiple sclerosis in African Americans: A cohort from southeast Texas. Int J MS Care. 2007;9(2):77-8.  [View poster]
    • Suarez-Zambrano GA, Perez F, Avila M, Hutton GJ, Rivera VM. Computer-assisted cognitive rehabilitation in patients with multiple sclerosis. Int J MS Care. 2007;9(2):93.  [View poster]
    American Academy of Neurology (AAN)
    59th Annual Meeting in Boston, Mass. (April 28 - May 5, 2007)
    • Cohen J, Calabresi P, Eickenhorst T, Edwards K, Felton W, Fisher E, et al. Results of the Avonex Combination Trial (ACT). Neurology. 2007;68(12 Suppl 1):A100.  [View poster]
    Mexican Academy of Neurology
    30th Annual Meeting in Merida, Yucatan, Mexico (Oct. 30 - Nov. 4, 2006)
    • Suarez-Zambrano GA, Perez F, Avila M, Hutton GJ, Rivera VM. Rehabilitación cognitiva asistida por computadora en pacientes con esclerosis múltiple. Rev Mex Neuroci. 2006;7(5):504.  [View poster]
    American Academy of Neurology (AAN)
    58th Annual Meeting in San Diego, Calif. (April 1-8, 2006)
    • Cohen J, Calabresi P, Edwards K, Eickenhorst T, Felton W, Fisher E, et al. Rationale, design, and baseline data for the Avonex Combination Trial (ACT). Neurology. 2006;66(5 Suppl 2):A32-3.